Immune checkpoint blockade in infectious diseases
Nature Reviews Immunology, ISSN: 1474-1741, Vol: 18, Issue: 2, Page: 91-104
2018
- 430Citations
- 712Captures
- 2Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations430
- Citation Indexes423
- 423
- CrossRef414
- Patent Family Citations7
- Patent Families7
- Captures712
- Readers712
- 712
- Mentions2
- Blog Mentions1
- Blog1
- News Mentions1
- News1
Most Recent Blog
Nature Reviews Immunology Contents February 2018 Volume 18 Number 2 pp 77-89
If you are unable to see the message below, click here to view. Advertisement Whitepaper: Continuous Live-Cell Analysis of the Immune-Tumor Axis Driving biological
Most Recent News
Single-Cell RNA Sequencing Reveals That C5AR1 in Follicle Monocyte Cells Could Predict the Development of POI
Introduction Female infertility and premature ovarian failure (POF) have become a global concern due to environmental pollution, tremendous life and work stress, and other factors.
Review Description
The upregulation of immune checkpoint molecules, such as programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte antigen 4 (CTLA4), on immune cells occurs during acute infections, such as malaria, as well as during chronic persistent viral infections, including HIV and hepatitis B virus. These pathways are important for preventing immune-driven pathology but can also limit immune-mediated clearance of the infection. The recent success of immune checkpoint blockade in cancer therapy suggests that targeting these pathways would also be effective for preventing and treating a range of infectious diseases. Here, we review our current understanding of immune checkpoint pathways in the pathogenesis of infectious diseases and discuss the potential for therapeutically targeting these pathways in this setting.
Bibliographic Details
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know